Re: Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial.
作者信息
Paolo Gontero, Francesco Soria
机构信息
Division of Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy.
Division of Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy.
出版信息
Eur Urol. 2023 Jun;83(6):580. doi: 10.1016/j.eururo.2023.01.008. Epub 2023 Jan 27.
PMID:36710204
Abstract
摘要
相似文献
1
Re: Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial.回复：中危非肌层浸润性膀胱癌患者辅助膀胱内热化疗与单纯化疗对比研究（HIVEC-II）：一项2期开放标签随机对照试验
Eur Urol. 2023 Jun;83(6):580. doi: 10.1016/j.eururo.2023.01.008. Epub 2023 Jan 27.
2
Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial.辅助性膀胱内化疗热疗与中危非肌肉浸润性膀胱癌患者的被动化疗（HIVEC-II）：一项 2 期、开放标签、随机对照试验。
Eur Urol. 2023 Jun;83(6):497-504. doi: 10.1016/j.eururo.2022.08.003. Epub 2022 Aug 20.
3
Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.回复：沈伟、亚伦·普伦德加斯特、夏洛特·阿克曼等。中危非肌层浸润性膀胱癌患者辅助膀胱内热化疗与单纯化疗的比较（HIVEC-II）：一项2期、开放标签、随机对照试验。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2022.08.003
Eur Urol. 2023 Feb;83(2):e47. doi: 10.1016/j.eururo.2022.10.027. Epub 2022 Nov 17.
4
Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackermann, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.回复：沈伟、亚伦·普伦德加斯特、夏洛特·阿克曼等人。中危非肌层浸润性膀胱癌患者辅助膀胱内热化疗与单纯化疗的比较（HIVEC-II）：一项2期开放标签随机对照试验。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2022.08.003
Eur Urol. 2023 Feb;83(2):e56-e57. doi: 10.1016/j.eururo.2022.09.035. Epub 2022 Nov 10.
5
Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.随机对照试验结果比较膀胱内化疗热疗与丝裂霉素 C 联合卡介苗用于中高危非肌层浸润性膀胱癌辅助治疗的比较。
Eur Urol. 2016 Jun;69(6):1046-52. doi: 10.1016/j.eururo.2016.01.006. Epub 2016 Jan 20.
6
Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.回复法比奥·坎波多尼科、弗朗西斯卡·马蒂奥利和卡洛·因托里尼致编辑的信，信的内容涉及：魏申·谭、亚伦·彭德加斯特、夏洛特·阿克曼等人。中危非肌层浸润性膀胱癌患者的膀胱内热化疗与单纯化疗对比研究（HIVEC-II）：一项2期开放标签随机对照试验。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2022.08.003 。
Eur Urol. 2023 Jan;83(1):e29-e30. doi: 10.1016/j.eururo.2022.10.009. Epub 2022 Oct 20.
7
Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.回复苏曼·萨胡、阿比谢克·潘迪、斯瓦伦杜·曼达尔、马诺伊·库马尔·达斯和普拉萨特·纳亚克致编辑的信，信的内容涉及魏申·谭、亚伦·彭德加斯特、夏洛特·阿克曼等人的《中危非肌层浸润性膀胱癌患者辅助膀胱内热化疗与单纯化疗的对比（HIVEC-II）：一项2期、开放标签、随机对照试验》。《欧洲泌尿外科杂志》待发表。https://doi.org/10.1016/j.eururo.2022.08.003 。
Eur Urol. 2023 Feb;83(2):e48-e49. doi: 10.1016/j.eururo.2022.11.006. Epub 2022 Nov 28.
8
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.顺铂热化疗与电动力给药治疗中高危非肌层浸润性膀胱癌的比较
Urol Oncol. 2023 Feb;41(2):109.e1-109.e8. doi: 10.1016/j.urolonc.2022.10.019. Epub 2022 Nov 12.
9
The efficacy of hyperthermic intravesical chemotherapy in high-risk non-muscle-invasive bladder cancer patients with BCG intolerance.高热膀胱内化疗对卡介苗不耐受的高危非肌肉浸润性膀胱癌患者的疗效。
Urologia. 2023 Nov;90(4):631-635. doi: 10.1177/03915603231189022. Epub 2023 Jul 20.
10
Re: Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C versus bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer.回复：一项随机对照试验的结果：比较膀胱内热化疗联合丝裂霉素C与卡介苗用于中高危非肌层浸润性膀胱癌患者辅助治疗的疗效
J Urol. 2018 Oct;200(4):696-697. doi: 10.1016/j.juro.2018.06.043. Epub 2018 Jul 7.
Zotero 插件